View : 26 Download: 0

Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome

Title
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
Authors
Ahn, Jae-SookKim, Yeo-KyeoungMin, Yoo HongCheong, June-WonJang, Jun HoJung, Chul WonKim, In HoYoon, Hwi-JoongLee, Hong GhiSohn, Sang KyunMoon, Joon HoKim, HawkKim, Yoo-JinWon, Jong-HoChung, Joo-SeopMun, Yeung ChulLee, Je-HwanKim, Hyeoung-JoonKorean Soc Hematology AML MDS Work
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2015
Journal Title
ACTA HAEMATOLOGICA
ISSN
0001-5792JCR Link1421-9662JCR Link
Citation
vol. 134, no. 1, pp. 40 - 48
Keywords
Myelodysplastic syndromeAzacitidineAllogeneic stem cell transplantation
Publisher
KARGER
Indexed
SCI; SCIE; SCOPUS WOS
Abstract
Azacitidine (AZA) is commonly used in patients with myelo-dysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twentyone patients who were scheduled for their third to sixth cycle of AZA pre-treatment followed by allo-SCT were enrolled. AZA pre-treatment was interrupted early in 3 patients (14.3%) because of leukaemic transformation or death. The overall response rate to AZA pre-treatment was 57.1%. There were 2 cases of complete remission, 1 case of partial remission, and 9 cases of haematologic improvement. Fourteen patients (66.7%) received the planned allo-SCT and 5 patients were alive at the last follow-up. Three-year progression-free survival (PFS) and 3-year overall survival (OS) in the 14 patients who received allo-SCT were 30.0% (95% CI 3.3-56.7) and 42.9% (95% CI 17.1-68.7), respectively. PFS and OS were not influenced by response to AZA pre-treatment (p > 0.05). In this study, AZA had a role as a bridge therapy to prevent leukaemic transformation prior to selection of a donor for allo-SCT and showed low toxicity. It may be considered in patients with higher-risk MDS. (C) 2015 S. Karger AG, Basel
DOI
10.1159/000368711
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE